Related Experiment Videos
Transfusion therapy in acquired coagulopathies
1Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville.
Hematology/Oncology Clinics of North America
|December 1, 1994
Summary
Acquired coagulopathies, like those in liver disease, involve multiple factor deficiencies and platelet issues. Non-transfusion treatments are gaining importance due to transfusion risks, but optimal strategies require further research.
Area of Science:
- Hematology
- Internal Medicine
Background:
- Acquired coagulopathies are complex bleeding disorders seen in conditions like liver disease, uremia, and disseminated intravascular coagulation.
- These disorders often involve multiple coagulation factor deficiencies, platelet dysfunction, and low platelet counts (thrombocytopenia).
Purpose of the Study:
- To review current treatment strategies for acquired coagulopathies.
- To highlight the growing role of non-transfusional therapies in managing bleeding risks.
Main Methods:
- Review of existing literature on acquired coagulopathies and their management.
- Analysis of the efficacy and risks associated with blood product transfusions versus alternative treatments.
Main Results:
- Blood products like fresh-frozen plasma and platelets can treat hemorrhage but have defined optimal regimens.
- Nontransfusional treatments, including desmopressin acetate and antifibrinolytic agents, are increasingly used due to transfusion-related risks (virus transmission, allergic/hemolytic reactions).
Conclusions:
- Optimal treatment regimens for acquired coagulopathies are still evolving.
- Further research is needed to establish the safest and most effective approaches for managing these hemostatic disorders.